View Clinical Trial (Medical Research Study)


Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

Signup
Browse Studies

City:   Philadelphia
State:   Pennsylvania
Zip Code:   19107
Conditions:   Sturge Weber Syndrome - Port-wine Mark
Purpose:   Primary Objective: • To assess the possible utility of topical timolol in the management of port-wine mark (PWM) in Sturge-Weber syndrome in children.
Study Summary:   Port-wine mark (PWM) represents a congenital capillary malformation,characterized by dilation and malformation of dermal capillaries that lack endothelial proliferation. It is frequently seen in the facial distribution of the trigeminal nerve. PWM persists throughout life and involves ~0.3% of the population. Although PWMs are found in other circumstances, ~ 3% of patients with facial PWM are also afflicted with Sturge-Weber syndrome. PWMs are cosmetic entities that often have serious social consequences, producing psychological trauma to both children and their parents. PWM does not involute with time, and, if left untreated, can develop deep purple coloration, tissue hypertrophy, and nodularity. Laser therapy, which selectively destroys specific targets within the skin, is currently the most commonly used approach for treating PWM, although complete blanching of the PWM after laser is rarely achieved for most patients, and only 10-45% of patients with Sturge-Weber have shown satisfactory outcomes. Complications of pulsed dye laser treatment for PWM include pyogenic granuloma, scabbing, cutaneous scarring, and permanent hypo/hyperpigmentation. Laser treatment is relatively contraindicated in children with darker skin coloration due to the resulting hypopigmentation which may be equally unsightly. Laser treatment causes substantial discomfort and pain to patients, and often requires general anesthesia in children. This is particularly true since earlier treatment in infancy is desirable and yields increased successful resolution of the PWM. The hypertrophic PWM in later years is resistant to any treatment. Recently, propranolol was reported to successfully treat capillary hemangioma in infants.13 While the mechanism by which beta blockade improves hemangioma is unclear, ß2-mediated vasoconstrictive effects and the ensuing apoptosis of capillary endothelial cells may contribute to the positive therapeutic results. Oral application of propranolol can cause severe systemic complications, including bronchospasm, vasospasm, hypoglycemia, hypotension, severe bradycardia, heart block, and congestive heart failure. Topical timolol solution, a β-blocker, has shown a similar ability to reduce capillary hemangioma of eyelids with little or no systemic effects in a small pilot study. Similar to capillary hemangioma, which is a proliferative lesion characterized by increased endothelial cell turnover, PWM is a capillary malformation with abnormal endothelial cells and large surface area of dilated capillaries. Thus, both capillary hemangioma and PWM share the similar characteristic of abnormal capillary endothelial cells. This pilot study is designed to explore the potential role of topical timolol in the management of PWM. As PWM is so frequently associated with Sturge-Weber syndrome, a disorder in which approximately 50% of patients will develop glaucoma, this study will be conducted in an ophthalmology setting. This study will consist of two arms. One group will receive timolol and the second group a placebo preservative free artificial tear gel. The groups will be divided with a ratio of 1:1 and the Timolol group will be matched with the placebo group by PWM location, age and race. Both medications are to be applied and rubbed in by fingertip to the treatment site twice a day for 6 months by subject's parents/guardian. (Treatment site: 1x1 cm at inferior edge of facial PWM) Follow-up schedule: 1 week after treatment initiation and then every 2 months for a period of six months.
Criteria:   Inclusion criteria: - Age from 2 years to 10 years - Port-Wine Mark - English fluent and literate substitute decision maker - Substitute decision maker vision sufficient to read informed consent document Exclusion criteria: - Active ocular infection (conjunctivitis, keratitis,) - History of systemic conditions including hypo/hypertension, hypoglycemia, bradycardia, asthma or any contraindication to beta blocker use - Unable to comply with required follow-up - Substitute decision maker not English fluent or not literate - Substitute decision maker unable to read consent document - Patient already using systemic beta-blocker or beta-agonist (Patients already using topical beta-blocker for glaucoma will not be excluded from study).
NCT ID:   NCT01533376
Primary Contact:   Principal Investigator
Alex V Levin, MD, MHSc
Wills Eye Institute

Jose A Cordovez, MD
Phone: 2159283418
Email: jcordovez@willseye.org
Backup Contact:   Email: alevin@willseye.org
Alex V Levin, MD, MHSc
Phone: 2159283918
Location Contact:   Philadelphia, Pennsylvania 19107
United States

Jose A Cordovez, MD
Phone: 215-928-3418
Email: jcordovez@willseye.org

Site Status: Recruiting

Data Source:   ClinicalTrials.gov
Date Processed:   August 27, 2015
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click I Am Interested In This Study

Full Name:
 
Email Address:
Confirm Email:
Daytime Phone (eg. 555-555-5555):
City:
State:
Zip Code:
Best Time to Call:
Questions/Comments:
  • NEARBY STUDIES

    (updated 31 minutes ago)
Within 25 Miles

Adolescent Depression - Cherry Hill NJ

Post-Traumatic Stress Disorder (PTSD) - Norristown PA

Attention Deficit Hyperactivity Disorder (ADHD) - Cherry Hill NJ

Depression - Cherry Hill NJ

Cushing's Syndrome - Philadelphia PA

Multiple Sclerosis - Willow Grove PA

Hepatitis B - Philadelphia PA

Polycystic Kidney Disease (PKD) - Autosomal Dominant (ADPKD) - Philadelphia PA

Polycystic Kidney Disease (PKD) - Autosomal Dominant (ADPKD) - Voorhees NJ

Multiple Sclerosis - Philadelphia PA

Major Depressive Disorder - Philadelphia PA

Spinal Cord Injury - Philadelphia PA

Early Alzheimer’s Disease - Jenkintown PA

Major Depressive Disorder - Philadelphia PA

Depression - Media PA

High Cholesterol - Wilmington DE

Within 50 Miles

Osteoarthritis - Downingtown PA

Polycystic Kidney Disease (PKD) - Autosomal Dominant (ADPKD) - Bethlehem PA

Polycystic Kidney Disease (PKD) - Autosomal Dominant (ADPKD) - Doylestown PA

High Cholesterol - Downingtown PA

High Cholesterol - Trenton NJ

Birth Control - Plainsboro NJ

Early Alzheimer’s Disease - Lawrence Township NJ

Asthma - Toms River NJ

Within 100 Miles

Leukemia or Lymphoma - Bronx NY

Leukemia or Lymphoma - Hershey PA

Metastatic Pancreatic Cancer - Towson MD

Osteoarthritis - Reading PA

Diabetic Foot Ulcers - Toms River NJ

Osteoarthritis (OA) of the Hip or Knee - New York NY

Diabetic Foot Ulcers (Sores) - Pasadena MD

Depression - New York NY

Temporomandibular Disorder (TMJD) - Baltimore MD

Postherpetic Neuralgia - New York NY

Social Anxiety Disorder - New York NY

Adult ADHD - New York NY

Depression - New York NY

Major Depression Disorder - New York NY

Treatment-Resistant Major Depressive Disorder - New York NY

Polycystic Kidney Disease (PKD) - Autosomal Dominant (ADPKD) - New York NY

Polycystic Kidney Disease (PKD) - Autosomal Dominant (ADPKD) - Jamaica NY

Psoriasis - New York NY

Cushing's Syndrome - New York NY

Cushing's Syndrome - Baltimore MD

Polycystic Kidney Disease (PKD) - Autosomal Dominant (ADPKD) - Baltimore MD

Herpes - Towson MD

Heart Attack - Towson MD

Depression - New York NY

Acne - New York NY

Memory Loss - New York NY

Depression - New York NY

Elderly Depression - New York NY

Crohn's Disease - New York NY

Recurrent Major Depressive Disorder - New York NY

Spinal Cord Injury - Baltimore MD

Healthy NON-Smokers - Catonsville MD

Osteoarthritis of the Knee - Towson MD

Premature Ejaculation - New York NY

Rheumatoid Arthritis - New York NY

HSDD (Decreased Sex Drive Woman) - New York NY

COPD - New York NY

Healthy Volunteers (Age 18-50) - Baltimore MD

Adult ADHD - New York NY

Major Depressive Disorder - New York NY

Healthy Female Volunteers (Age 18-35) - Baltimore MD

Type 2 Diabetes - Hackensack NJ

High Cholesterol - Martinsville NJ

Polycystic Kidney Disease (PKD) - Autosomal Dominant (ADPKD) - Mineola NY

Chronic Fatigue Syndrome - New York NY

Asthma - New York NY

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - New York City NY

Schizophrenia - New York NY

Healthy Volunteers (Age 18-50) - Baltimore MD

Type 2 Diabetes - Baltimore MD

Ischemic Stroke - Baltimore MD

High Cholesterol - Baltimore MD

High Cholesterol - Nottingham MD

High Cholesterol - Lutherville Timonium MD

Asthma - Baltimore MD

Genital Warts - New York NY

Healthy Volunteers (Age 18-65) - Baltimore MD

Asthma in Children - Highland Park NJ

Asthma in Children - New York NY

Asthma in Children - White Marsh MD

Polycystic Kidney Disease (PKD) - Autosomal Dominant (ADPKD) - Cooper NY

Healthy Male Volunteers (Age 18-65) - Baltimore MD

Early Alzheimer’s Disease - Wilkes Barre PA

High Cholesterol - New York NY

Major Depressive Disorder - New York NY

Healthy Volunteers (Age 18-55) - Baltimore MD

High Cholesterol - New York NY

Migraines - Queens NY

Ischemic Stroke - Baltimore MD

Diabetic Foot Ulcers - Baltimore MD

High Cholesterol - Towson MD

Asthma - Asbury Park NJ

Asthma - Brooklyn NY

Healthy Volunteers (Age 18-55) - Baltimore MD